Bolt Biotherapeutics, Inc. (BOLT) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
BOLT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BOLT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -469.3% | -433.7% |
| 2024 | 100.0% | -949.9% | -820.8% |
| 2023 | -681.4% | -967.4% | -878.6% |
| 2022 | -1176.4% | -1576.6% | -1537.8% |
| 2021 | -5904.4% | -7364.1% | -7824.7% |
Download Data
Export BOLT earnings history in CSV or JSON format
Free sign-in required to download data
Bolt Biotherapeutics, Inc. (BOLT) Earnings Overview
As of May 6, 2026, Bolt Biotherapeutics, Inc. (BOLT) reported trailing twelve-month net income of -$33M, reflecting -981.8% year-over-year growth. The company earned $-17.85 per diluted share over the past four quarters, with a net profit margin of -433.7%.
Looking at the long-term picture, BOLT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2018.
Bolt Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), AGEN ($115,000 net income, 0.1% margin), IMVT (-$464M net income), BOLT has room to improve margins relative to the peer group. Compare BOLT vs RCUS →
BOLT Earnings vs Peers
Earnings metrics vs comparable public companies
BOLT Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$33M | +47.1% | -$36M | $-17.85 | -433.7% | -469.3% |
| 2024 | -$63M | +8.8% | -$73M | $-1.65 | -820.8% | -949.9% |
| 2023 | -$69M | +21.5% | -$76M | $-1.83 | -878.6% | -967.4% |
| 2022 | -$88M | +10.6% | -$90M | $-2.30 | -1537.8% | -1576.6% |
| 2021 | -$99M | -62.3% | -$93M | $-2.79 | -7824.7% | -7364.1% |
| 2020 | -$61M | -99.2% | -$49M | $-1.99 | -26289.2% | -21290.9% |
| 2019 | -$30M | -163.1% | -$31M | $-3.75 | -14180.0% | -14404.2% |
| 2018 | -$12M | - | -$12M | $-5.96 | - | - |
See BOLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BOLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BOLT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBOLT — Frequently Asked Questions
Quick answers to the most common questions about buying BOLT stock.
Is BOLT growing earnings?
BOLT EPS fell to $-17.85, with earnings declining -981.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-33M.
What are BOLT's profit margins?
Bolt Biotherapeutics, Inc. net margin is -433.7%, with operating margin at -469.3%. Below-average margins reflect competitive or cost pressures.
How consistent are BOLT's earnings?
BOLT earnings data spans 2018-2025. The declining earnings trend is -981.8% YoY. Historical data enables comparison across business cycles.